The Acostic Neuroma (Auditory Nerve Tumor) drugs in development market research report provides comprehensive information on the therapeutics under development for Acostic Neuroma (Auditory Nerve Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acostic Neuroma (Auditory Nerve Tumor). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acostic Neuroma (Auditory Nerve Tumor) and features dormant and discontinued products.

GlobalData tracks six drugs in development for Acostic Neuroma (Auditory Nerve Tumor) by six companies/universities/institutes. The top development phase for Acostic Neuroma (Auditory Nerve Tumor) is phase ii with three drugs in that stage. The Acostic Neuroma (Auditory Nerve Tumor) pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Acostic Neuroma (Auditory Nerve Tumor) pipeline products market are: AstraZeneca, Millennium Pharmaceuticals and Novartis.

The key targets in the Acostic Neuroma (Auditory Nerve Tumor) pipeline products market include Vascular Endothelial Growth Factor (VEGF) , Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1), and Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1).

The key mechanisms of action in the Acostic Neuroma (Auditory Nerve Tumor) pipeline product include Histone Deacetylase (HDAC or EC 3.5.1.98) Inhibitor with one drug in Phase 0. The Acostic Neuroma (Auditory Nerve Tumor) pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Acostic Neuroma (Auditory Nerve Tumor) pipeline products market including Small Molecule, and Gene Therapy.

Acostic Neuroma (Auditory Nerve Tumor) overview

Acoustic neuroma or vestibular schwannoma is a noncancerous, usually slow growing tumor affecting balance and auditory nerves. It is of two types: sporadic unilateral acoustic neuroma and genetic, bilateral acoustic neuroma. Hearing loss, dizziness, tinnitus, eye fullness, balance problems and vertigo, numbness in the face, and swallowing problems are some of the signs and symptoms. It can be diagnosed through audiometry and imaging of head. Surgery or stereotactic radiosurgery can be an effective treatment.

For a complete picture of Acostic Neuroma (Auditory Nerve Tumor)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.